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Abstract
Background: Pulmonary hypertension (PH) refers to a spectrum of diseases with elevated pulmonary artery
pressure. Pulmonary arterial hypertension (PAH) is a disease category that clinically presents with severe PH and
that is histopathologically characterized by the occlusion of pulmonary arterioles, medial muscular hypertrophy,
and/or intimal fibrosis. PAH occurs with a secondary as well as a primary onset. Secondary PAH is known to be
complicated with immunological disorders. The aim of the present study is to histopathologically and genetically
characterize a new animal model of PAH and clarify the role of OX40 ligand in the pathogenesis of PAH.
Results: Spontaneous onset of PAH was stably identified in mice with immune abnormality because of
overexpression of the tumor necrosis factor (TNF) family molecule OX40 ligand (OX40L). Histopathological and
physical examinations revealed the onset of PAH-like disorders in the C57BL/6 (B6) strain of OX40L transgenic mice
(B6.TgL). Comparative analysis performed using different strains of transgenic mice showed that this onset depends
on the presence of OX40L in the B6 genetic background. Genetic analyses demonstrated a susceptibility locus of a
B6 allele to this onset on chromosome 5. Immunological analyses revealed that the excessive OX40 signals in TgL
mice attenuates expansion of regulatory T cells the B6 genetic background, suggesting an impact of the B6
genetic background on the differentiation of regulatory T cells.
Conclusion: Present findings suggest a role for the OX40L-derived immune response and epistatic genetic effect
in immune-mediated pathogenesis of PAH.
Background
Pulmonary hypertension (PH) is a severe disease condition
that can lead to progressive right ventricular failure and
ultimately to death. Pulmonary arterial hypertension
(PAH) is a major class of PH defined in the classification
of the World Health Organization (WHO). The main his-
topathological manifestations of PAH are vasoconstriction,
endothelial cell proliferation and fibrosis, smooth-muscle
cell proliferation, and thrombosis in small pulmonary
arteries. These changes result in elevation of pulmonary
vascular resistance and, consequently, in pulmonary arter-
ial pressure [1].
PAH occurs as either a primary (idiopathic or familial)
or a secondary disease. According to the WHO classifica-
tion, inflammatory conditions, such as collagen vascular
diseases, and viral infections are associated with the
occurrence of PAH. Indeed, patients with a subset of
idiopathic PAH have some inflammatory disturbances,
presented as elevated circulating levels of TNF-a,i n t e r -
leukin (IL)-1, and IL-6 [2]. In the case of severe PAH in
humans, infiltration of immune cells, including T cells, B
cells, and macrophages, is occasionally observed in pul-
monary vascular lesions [3]. Most of the CD4
+ and CD8
+
T cells infiltrating into the intimal lesions have been
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cating the active status of the T cells. In animal models,
augmented expression of IL-18 or administration of IL-6
is sufficient to induce mild spontaneous PH [4,5]. In the
former case, IL-13 has been shown to critically mediate
inflammatory signals in the lung. Recent studies have
proposed that naturally arising CD4
+CD25
+ regulatory T
(Treg) cells, or their mediators, may inhibit the develop-
ment of experimental PH [6]. Furthermore, it has been
suggested that the deficiency of CD4
+ T cells in humans
(e.g., in cases of HIV infection), or the depletion of CD4
+
T cells in experimental animal models, is associated with
the development of PAH [7]. These observations impli-
cate an immune-mediated mechanism in the develop-
ment of PAH.
Signals through T-cell costimulatory molecules are criti-
cally involved in eliciting optimal T-cell functions [8].
OX40 (TNFRSF4, CD134) is a member of the TNF recep-
tor superfamily that is transiently expressed on activated
T cells. The ligand of OX40 (OX40L: TNFSF4, CD134L) is
mainly expressed on mature antigen-presenting cells as
well as on vascular endothelial cells [9-12]. The OX40-
OX40L interaction is required for optimal effector func-
tion of T cells [13,14] and generation of memory T cells
[15-18]. Recently, growing evidence has unveiled the
importance of OX40 signals in the accumulation of effec-
tor CD4
+ T cells at inflammation sites in mouse models of
autoimmune diseases. Moreover, a recent study has
demonstrated that constitutive OX40-OX40L interactions
in OX40L transgenic mice entail spontaneous develop-
ment of ulcerative colitis-like disease and an undetermined
lung disease, which is accompanied by significant produc-
tion of an anti-DNA antibody [19]. Interestingly, these
pathological manifestations have been observed in mice
with the C57BL/6 (B6) genetic background but not in
those with the BALB/c (BALB) genetic background. The
strain-specific pathological manifestations implicate the
presence of a genetic predisposition that modulates
OX40L-dependent inflammation in the colon and lungs.
The goal of this study was to characterize the undeter-
mined lung disease presented in an OX40L-transgenic B6
strain (B6.TgL) of mice. In the present study, we proposed
a new spontaneous model for PAH. Furthermore, this
study provided novel insight into the role of the OX40L-
derived signal and the genetic predisposition in the
immune-mediated pathogenic mechanism of PAH.
Methods
Mice
Mice with OX40L transgene under the expression con-
trol of lck promoter were generated in a C57BL/6 genetic
background as described previously (B6.TgL) [19]. To
generate OX40L transgenic mice on BALB/c background
(BALB.TgL), B6.TgL backcrossed to BALB/c strains
more than 8 times. Age and sex-matched wild-type
C57BL/6 and BALB/c were used as controls. For genetic
analyses, TgL mice with mixed genetic background were
prepared by the mating of BALB × B6.TgL and (BALB ×
B6) F1 × B6.TgL. All mice were bred and maintained in
conventional clean room in the animal department of the
Oriental Bio-service, Co. Ltd, Shizuoka, Japan. In all ani-
mal experiments in this study, we followed the Tohoku
University guidelines for animal experimentation.
Histopathological examinations
At 20 weeks of age, each mouse was killed under ether
anesthesia. The whole lung was immersion fixed in 10%
formalin in 0.01 M phosphate buffer (pH 7.2), and
embedded in paraffin. Tissue sections were stained with
hematoxylin and eosin (H&E) and Masson’s trichrome
for light-microscopic examination. The disease score of
PAH was histopathologically determined. Ten small pul-
monary arteries along with terminal bronchioles were
individually graded under microscopic examination
according to following histopathological criteria: 0, nor-
mal; 1, significant, slight thickening of the media; 2,
thickening of the media with intimal (endothelial) prolif-
eration and/or fibrosis. A mean grade of all points
examined was considered as an individual PAH score.
Immunohistochemical analyses were performed using
the primary antibodies to human a-smooth muscle
actin (aSMA) (DACO, Tokyo, Japan), which has been
shown to react mouse aSMA, and mouse CD31 (Santa
Cruz Biotechnology, Santa Cruz, CA).
Right ventricular systolic pressure measurements
B6, BALB, B6.TgL, and BALB.TgL mice were anesthe-
tized by intraperitoneal injection of ketamine hydro-
chloride (60 mg/kg) and xylazine (8 mg/kg) or, in the
second series of measurement using B6, and BALB.TgL
mice, pentobarbital sodium (50 mg/kg). Right ventricu-
lar systolic pressure (RVSP) was measured in sponta-
neously breathing mice by direct puncture of the right
ventricle with a 25-gauge needle connected to a pressure
transducer [20]. In the second series with the pentobar-
bital anesthetization, it was measured in artificially ven-
tilated mice with median thoracotomy.
Evaluation of right ventricular hypertrophy
The hearts isolated from B6, BALB, B6.TgL, and BALB.
TgL mice were fixed in formalin and dissected into
right ventricle (RV), left ventricle (LV), and interventri-
cular septum (IVS). The dissected ventricles were care-
fully washed in saline to remove blood clots and
separately weighted. Right ventricular hypertrophy was
evaluated by the weight ratio of RV/(LV+IVS).
Rabieyousefi et al. BMC Immunology 2011, 12:67
http://www.biomedcentral.com/1471-2172/12/67
Page 2 of 12Antibodies and flow cytometric analysis
Anti-CD3-FITC, anti-CD4-allophycocyanin, anti-CD25-
allophycocyanin, anti-CD44-phycoerythrin (PE), anti-
CD62L-FITC, and anti-IL-17-PE were purchased from BD
Biosciences (San Diego, CA). Anti-mouse Foxp3-PE (FJK-
16S) was purchased from eBioscience (San Diego, CA).
Anti-mouse CD3ε (clone 2C11) used for T cell stimulation
and anti-mouse CD16/32 (clone 2.4G2) used for Fc recep-
tor blocking were purified from hybridoma-cultured
supernatants in our laboratory. Cells were incubated with
antibodies for 30 min at 4°C and then washed to remove
unbound antibodies. All the samples were analyzed with a
FACSCalibur™ flow cytometer and the CellQuest™ pro-
gram (BD Biosciences).
Preparation of lymphocyte culture and cytokine
measurements
Single-cell suspensions were prepared from spleen and
lungs of an 8 to 10 week-old mouse, in which the lung
disease of interest is not developed. Lymphocytes in the
lung were obtained by digesting minced lung tissues with
150 U/ml collagenase (Maeda Co. Ltd., Tokyo, Japan) as
described previously [21]. The number of effector/mem-
ory and regulatory T cells were calculated based on
the percentage of each subpopulation that was
CD44
highCD62L
low and CD4
+Foxp3
+, respectively, and
the total cell number in each organ. Total lymphocytes
isolated from lung tissues that contained equal number
of effector/memory CD4
+T cells (normalized based on
absolute number of effector/memory CD4 T cells) were
stimulated with soluble anti-CD3ε (10 μg/ml) at 37°C for
the indicated time. IL-13 levels were assayed in cultured
supernatants using ELISA kit for IL-13 (R&D Systems,
Minneapolis, MN), according to the manufacturer’s
recommendations. The production of IL-17 in lympho-
cytes was detected by intracellular staining with anti-IL-
17-PE following incubation of lymphocytes for 4 h with
50 ng/ml PMA, 500 ng/ml Ionomycin (Sigma-Aldrich, St.
Louis, MO) in the presence of 10 μg/ml brefeldin A
(Invitrogen, Carlsbad, CA).
Genetic mapping
Genotypes of BCN2.TgL mice were determined by poly-
merase chain reaction (PCR) using genomic DNA pre-
pared from the tail tip. The genotyping PCR was
performed using standard reagent and the following con-
ditions: 94°C for 5 min, 35 cycle of 94°C for 30 sec, 58°C
for 30 sec, 72°C for 30 sec, and final extension 72°C for
5 min with the 98 microsatellite markers (additional file
1), which represent amplified fragment-length poly-
morphism between BALB and B6 strains. This genotyp-
ing provided full coverage of the mouse autosomes with
the marker spaced an average of 12.5 cM apart and a
maximum distance of 35 cM between any two markers.
PCR products were visualized with electrophoresis on
2-4% agarose gels containing 0.01% ethidium bromide.
In a genome-wide scan, we determined genotypes of
the 48 BCN2.TgL mice, which were selected as the top
(severest) 24 and the bottom 24 on the list of PAH
score, at all the 98 microsatellite positions (additional
file 1) . The association at each microsatellite position
was evaluated with chi-square test for independence
between the genotypes and the two groups that were
positive and negative for the incidence of PAH, using
standard 2 × 2 contingency matrices. A p value less
than 0.05 was regarded as suggestive association. The
suggestive association was confirmed by the two-tail
t-test for the difference of means between the two geno-
type groups of a total of 341 BCN2.TgL mice. In this
test a P value less than 0.0034 was regarded as sugges-
tive association. This P threshold was referred to the
previous recommendation [22].
In a linkage mapping, a linkage position was deter-
mined with the quantitative trait locus (QTL) program.
The logarithm of odd (LOD) was determined with the
interval mapping program in the Windows QTL Carto-
grapher (V2.5) software. The PAH scores of all BCN2.
TgL mice were used as an indicator of phenotype.
A suggestively significant level (a = 0.05) of LOD was
determined by the permutation test installed in this soft-
ware (1000 permutations). Map positions (cM) of the
microsatellite makers were based on the information of
the Mouse Genome Database of The Jackson Laboratory
(http://www.informatics.jax.org).
Statistics
A 95% confidence interval shown in Table 1 was calcu-
l a t e du s i n gt h em e t h o dd e s c r ibed previously [23]. The
two-tailed t-test was used to evaluate a difference of
Table 1 Summary of PAH scores of B6, BALB, and
transgenic strains of mice
Mice* n† Median of score 95% CI‡ Statistics§
B6 9 0 0 - 0.1
BALB 2 0 n.d.
B6. TgL 15 0.7 0.35 - 1.05 ¶
BALB. TgL 8 0 0 - 0.1
BCF1. TgL 30 0.05 0 - 0.1
BCN2. TgL female 174 0.25 0.2 - 0.4 ¶
BCN2. TgL male 167 0.25 0.2 - 0.4 ¶
* All mice were killed at 20 week-old for this examination. BCF1, BALB × B6;
BCN2, BCF1 × B6.TgL.
† Number of mice tested.
‡ CI, confidential interval. The CI was not determined (n.d.) for BALB/c (BALB).
§ The significance of this study was evaluated by Mann-Whitney U-test for the
all strains.
¶, P < 0.01 (v.s. B6).
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considered as significant.
Results
Histopathological characterization of the lung phenotype
Microscopic examination revealed diffuse pathological
changes in the small- to medium-sized pulmonary arteries
in B6.TgL (Figure 1A, E), but not in B6 (Figure 1B), BALB
strain of OX40L transgenic mice (BALB.TgL) (Figure 1C),
or BALB (Figure 1D). This vascular lesion was found to be
readily accompanied with perivascular infiltration of lym-
phocytes and, to a lesser extent, neutrophils (Figure 1F).
These changes were mainly observed in arteries contained
in bronchovascular bundles (respiratory arteries) and were
typically characterized by fibrocellular endothelial prolif-
eration of the intimal layer and, to a lesser extent, medial
muscular hypertrophy (Figure 1G and 1H). Neither
muscularization of distal pulmonary arterioles, which is a
common pathological change in a hypoxic PAH model,
nor plexiform lesions, found in human PAH, were identi-
fied. The cells in the intimal lesion were characterized as
positive for a myofibroblast marker, smooth muscle-
specific actin (aSMA) (Figure 1I), and an endothelial cell
marker, CD31 (Figure 1J). When no treatment was admi-
nistered to avoid vasospasm before the histopathological
preparation, vasoconstriction was frequently observed in
pulmonary arteries of B6.TgL but not in wild-type B6,
BALB, and BALB.TgL mice, irrespective of the presence of
the overt pathological changes mentioned above (data not
shown). Perivascular lymphocytic infiltration was also
observed around pulmonary veins; however, there was no
pathologic remodeling in those veins as observed in the
Figure 1 Histopathological features of the lung disease in B6.TgL mice. (A-D) Histopathological manifestation typically present in B6.TgL (A).
No pathological manifestation observed in B6 (B), BALB.TgL (C), and BALB (D). The photograms indicated were taken from over 20-week aged
male mouse. Arrow heads indicate pulmonary arteries. TB, terminal bronchiole. H&E staining. Scale bar = 100 μm. (E) Diffuse pathology present in
B6.TgL. Masson’s trichrome staining. Scale bar = 1 mm. (F) Perivascular lymphocytic infiltration in the affected lung. H&E staining. Scale bar = 50
μm. (G, H) Representative microscopic appearance in the affected arteries in the B6.TgL lung. An inset photogram in G represents the
appearance of a normal pulmonary artery. Thickening of the intimal and, to a lesser extent, medial layers with marked intimal fibrosis is
characteristic of the affected arteries. Masson’s trichrome staining. Scale bar = 100 μm. I and J, expression of aSMA and CD31 (PECAM),
respectively in the thickened arterial wall. The photogram in the inset of J represents a normal manifestation of unaffected artery.
Immunohistochemical staining with hematoxylin counter-staining. Scale bar: in I, 200 μm; in J, 100 μm.
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vascular lesions were not observed in conjunction with the
perivascular infiltration, indicating that the vascular lesion
of interest is not related to any type of vasculitis syndrome.
We found no vascular lesions in the kidney or the colon of
B6.TgL mice. Thus, the spontaneous lung disease in B6.
TgL mice was characterized by lung-specific, pulmonary
artery-restricted intimal thickening with lymphocytic
(chronic) inflammation. These histopathological character-
istics are similar yet distinct in a few points from those of
human PAH.
Strain-restricted onset of the lung disease
The PAH-like disease, as defined in the B6.TgL mice, was
quantified with a PAH score in other strains of mice,
including B6, BALB, BALB.TgL, BALB × B6.TgL (BCF1.
TgL), and (BALB × B6) F1 × B6.TgL (BCN2.TgL). It was
observed that wild-type and different TgL strains, such as
BALB.TgL and BCF1.TgL, barely developed the PAH-like
disease (Table 1). On the other hand, BCN2.TgL devel-
oped a PAH-like disease with a broader distribution of the
PAH score than B6.TgL. There were no sex-related differ-
ences in the PAH scores (Table 1). These findings indicate
that development of the PAH-like disease depends on
both the effects of TgL and on an undefined B6-specific
genetic background.
Elevation of RV systolic pressure and RV hypertrophy in
B6.TgL
The PAH-like arteriopathy in B6.TgL mice indicated the
onset of clinical PH. We therefore measured right ventri-
cular (RV) systolic pressure (RVSP) in aged B6.TgL,
BALB.TgL, and their wild-type strains. RVSP was signifi-
cantly increased in the B6.TgL mice, as compared to B6
(Figure 2A). Importantly, the RVSP values were signifi-
cantly correlated with the PAH scores (Figure 2B).
Furthermore, significant RV hypertrophy was demon-
strated for B6.TgL, as compared to B6 mice (Figure 2C).
Increases in RVSP and RV hypertrophy were not observed
in the BALB.TgL mice, as compared to B6 mice (addi-
tional file 2). In other experiments performed using wild-
type BALB mice (30 w), there has been no evidence for
RV hypertension or RV hypertrophy in BALB strain:
RVSP = 21.3 ±2.72 mmHg, RV/(LV + IVS) = 0.25 ±0.026.
Accumulation of effector/memory CD4
+ T cells in
OX40L-Tg mice
Previous studies performed with B6.TgL mice have demon-
strated a selective increase in the number of
CD44
highCD62L
low effector/memory CD4
+ T cells in lym-
phoid and nonlymphoid tissues [17,19]. We examined
whether the tissue distribution of effector/memory CD4
+ T
cells was altered by the genetic background before the dis-
ease onset. Flow cytometric analyses revealed a significant
increase in the number of effector/memory CD4
+ T cells
in both the spleen (Figure 3A and 3B) and lungs (Figure
3C and 3D) in every TgL mouse examined. Importantly,
this increase was not observed in a strain-specific manner,
indicating that the development of PAH is not simply
explained by the increase of effector/memory CD4
+ Tc e l l s .
Strain-specific profile of cytokine production by the lung
CD4
+ T cells
The functionality of resident CD4
+ T cells in the lungs of
TgL mice was determined by testing their ability to pro-
duce cytokines in response to anti-CD3 or PMA/ionomy-
cin stimulation, respectively. Augmented IL-13 production
was observed in the TgL-derived T cells and interestingly,
this augmentation was greater in B6.TgL than in BALB.
TgL (Figure 4A). Furthermore, a larger number of IL-17-
producing CD4
+ T cells were observed in B6.TgL mice
than in BALB.TgL (Figure 4B). IL-4 and IL-5 were not
detected in stimulated lung cells by any strains (data not
shown). These results indicate that the function of tissue
resident CD4 T cells can be modulated by the excessive
OX40 signals on B6 genetic background before disease
onset.
Over-expression of OX40L in B6 background alters the
balance between lung resident effector/memory T cells
and regulatory T cells
CD4
+CD25
+Foxp3
+ T cells, usually denoted as Treg cells,
are known to control inflammatory responses by suppres-
sing the activities of Foxp3
- effector T cells [24]. Several
independent studies have demonstrated that lung resident
Treg cells suppress type 2 immune responses and, conse-
quently, reduce pulmonary inflammation [25-27]. We ana-
lyzed the population size of Treg cells, defined as CD4
+Foxp3
+, in the lung of non-transgenic and TgL strains.
Flow cytometric analyses revealed that the frequency and
absolute number of Treg cells increased in TgL strains in
advance of the disease onset as compared with those in
nontransgenic strains (Figure 5A and 5B). It was particu-
larly noted that the increase of Treg was less in B6.TgL
than in BALB.TgL, suggesting that B6-specific genetic fac-
tors counteract development of Treg cells in TgL mice. We
also examined the ratio of Foxp3- effector/memory CD4 T
cells (additional file 3) to Foxp3+ Treg before disease onset.
The data shows an increased ratio of effector/memory T
cells to Treg cells in the B6.TgL lung compared to the
BALB.TgL lung (Figure 5C). These findings also suggest
an important role of Treg in regulating inflammation asso-
ciated with the pathogenesis of PAH-like disease in B6.
TgL mice.
Identification of a susceptibility locus for PAH
TgL-dependent PH developed in a strain-specific man-
ner, suggesting that the genetic background had an effect
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locus for a PAH-like disease in B6.TgL, a genetic
approach was employed using BCN2.TgL mice, which
are descended from the B6.TgL and non-disease-prone
BALB.TgL strains of mice. A genome-wide scan per-
formed using selected 48 BCN2.TgL mice identified 4
candidate loci on chromosomes 5, 9, 13, and 17, which
were possibly associated with the incidence of a PAH-like
disease (additional file 1). The association study with 341
BCN2.TgL mice confirmed the suggestive association at
D5Mit346 (1 cM) and D5Mit381 (8 cM) on chromosome
5( T a b l e2 ) .T h eo t h e rc a n d i d a t el o c ip r e l i m i n a r i l y
defined on chromosomes 9, 13, and 17 were not con-
firmed by this study. A QTL analysis consistently demon-
strated a suggestive linkage between the level of PAH
score and the chromosomal region between D5Mit346
and D5Mit381. This linkage was observed in a single
LOD peak of 2.4 at 7 cM on chromosome 5 (Figure 6).
Discussion
Previous studies have shown that B6.TgL mice display
abnormal T-cell differentiation and functions, and spon-
taneous inflammation in the colon and lung. The colo-
nic phenotype in B6.TgL mice was histopathologically
defined as an inflammatory bowel disease resembling
ulcerative colitis in humans. In the present study, the
undetermined lung disease in B6.TgL mice was charac-
terized as a PAH-like disease. PAH is a clinical category
of PH that comprises many different disease entities.
Pathological manifestations of the PAH-like disease in
B6.TgL mice are not completely parallel to those of idio-
pathic PAH. The differences between idiopathic PAH
Figure 2 Clinicopathological phenotypes associated with PH. (A) Significant elevation of RVSP (mmHg) in B6.TgL. The result represents a
mean ± standard deviation (SD) of 4 B6 or 6 B6.TgL mice (20 to 24 weeks old) for each group. (B) Correlation between RVSP values and PAH
scores obtained from the 10 mice examined in A. The significance of this correlation was confirmed with the Kendall tau (τ) rank correlation
coefficient (τ = 0.828). (C) RV hypertrophy manifested in B6.TgL. RV hypertrophy was evaluated with the index provided by the formula,
RV/(LV+IVS). The result represents a mean ± SD of 12 B6 or 8 B6.TgL mice for each group. The significant difference between the two groups
was evaluated by two-tailed t-test. *, p < 0.05; **, p < 0.01.
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+ cells in transgenic (TgL) strains of mice. The percentages of CD44
highCD62L
lowCD25
-CD4
+ T cells (effector/memory CD4
+T cells) in a total of CD4
+T cells are shown in the dot grams; (A) spleen, (C) lung. The absolute numbers of
effector/memory CD4
+ T cells are shown in the bar grams; (B) spleen, (D) lung. The absolute number was calculated from the percentage of this
subset and the total cell number in each organ. The results represent a mean ± SD of 6-8 mice per each group. The results of flow cytometry (A
and C) are representative of three independent experiments performed using 8 to 10 week-old mice. The significant difference between the two
groups was evaluated by two tailed t-test. *, p < 0.01; **, p < 0.001.
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affected arteries, the primarily affected layer of vascular
wall, and the participation of massive lymphocytic peri-
vascular infiltration. Further investigations are needed to
define the present lung pathology as any type of PAH.
An increasing body of evidence implicates the role of
immune-mediated mechanisms in the pathogenesis of
PAH. A type of PAH occurs secondarily to collagen vas-
cular disorders, such as systemic sclerosis and mixed
connective tissue disease (MCTD). Interestingly, PAH
with MCTD presents with a prominent characteristic of
endothelial degeneration and proliferation, probably due
to the pathogenic contribution of autoantibodies to
endothelial cells [28,29]. This characteristic may be a
pathological consequence of immune-mediated mechan-
isms shared with the present model. The findings in the
B6.TgL mice provide a possible insight into an implica-
tion of an OX40L-derived signal in the immune-
mediated mechanism of endothelial pathology in PAH.
PAH is associated with endothelial cell dysfunction
and vasoconstriction. There is no direct evidence for a
link between these pulmonary vascular manifestations
and abnormality in situ of OX40L-derived signal.
However, it has been shown that OX40L-derived signals
have a pathologic impact on the endothelial cell func-
tions of systemic arteries. Recent studies have demon-
strated an association of OX40L gene polymorphism
with the susceptibility to atherosclerosis in humans [30],
and the critical contribution of OX40-OX40L interac-
tions to atherogenesis in low-density lipoprotein recep-
tor-deficient mice [31]. The endothelial cells of the
systemic arteries and those of the pulmonary arteries
are exposed to different conditions, i.e., blood pressure
and oxygen tension. It is interesting to know whether
the OX40-OX40L interactions yield a different response
on pulmonary endothelial cells than on systemic
endothelial cells, and whether the OX40L gene poly-
morphism is associated with any type of PAH in
humans.
Our present immunological studies performed using
TgL and non-TgL strains of mice with different genetic
backgrounds–B6 and BALB–revealed the respective
effects of TgL and strain-dependent genetic background
on immune phenotypes in the lung. Previous studies
have demonstrated that OX40L-derived signals promote
the expansion of effector/memory CD4
+ Tc e l l s[ 1 7 , 1 9 ]
Figure 4 Strain-specific cytokine profile in lung CD4
+T cells. (A) IL-13 production from a total of lymphocytes isolated from the lung of non-
transgenic and transgenic (TgL) strains of mice at 8 to 10 week-old. Lymphocytes containing equal number of CD44
highCD62L
lowCD4
+T cells for
each group (n = 4) of strain were stimulated with soluble anti-CD3 for 48 h and IL-13 in the cultured supernatant was quantified by ELISA. The
significant difference between B6.TgL and BALB.TgL was evaluated by two-tailed t-test. *, p < 0.05. (B) IL-17 production in the lung CD4
+T cells.
Lymphocytes isolated as above were incubated with PMA/Ionomycin in the presence of brefeldin A for 4 h and intracellular IL-17 production
was analyzed in CD4 T cells. Representative data from two independent experiments were shown.
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duction of IL-13 and IL-17 by CD4
+ T cells [33-35]. To
examine which TgL-dependent immune aberrations are
correlated with the onset of the PAH-like disease, we
examined TgL-dependent immune phenotypes in the
lungs of 2 different strains at a pre-disease stage. The
findings indicate that B6-specific genetic factors influence
the expansion of effector/memory CD4
+ Tc e l l sa n dT reg
cells in advance of the onset of lung disease. A possible
role of Treg cells has been documented in the
Figure 5 Accumulation of Treg cells in non-transgenic and transgenic (TgL) strains of mice at 8 to 10 week-old. The percentage (A) and
absolute numbers (B) of CD4
+ Foxp3
+Treg cells in the lung are shown. The absolute lymphocytic number was calculated from the percentage of
Treg and the total cell number. (C) The ratio of effector/memory T cells (CD4+ CD25- CD44
high CD62L
low) to Fopx3+ Treg cells in the lung. A
significant increase in this ratio is shown in B6.TgL strain of mice. The result represents a mean ± SD from 4 mice per each group. The results of
flow cytometry (A) are representative of two independent experiments. The significant difference between the two groups was evaluated by
two tailed t-test. *, p < 0.01; **, p < 0.001.
Table 2 Genetic association of PAH score in BCN2
Marker Position (CM) Mean of grade† Mean of grade P value‡
BB BC
D5Mit346 1 0.51 ± 0.61 (172) 0.32 ± 0.46 (169) 0.0018 §
D5Mit381 8 0.51 ± 0.59 (178) 0.32 ± 0.46 (163) 0.0012 §
D5Mit197 36 0.46 ± 0.56 (192) 0.36 ± 0.52 (149) 0.0844
D5Mit338 59 0.45 ± 0.55 (191) 0.37 ± 0.53 (150) 0.1476
D5Mit213 70 0.41 ± 0.52 (192) 0.42 ± 0.58 (149) 0.9149
D5Mit409 83 0.42 ± 0.55 (165) 0.41 ± 0.54 (178) 0.766
* Values indicate mean ± SD and the values in parenthesis denote the number of mice.
† BB = B6 homozygote; BC = B6/BALB heterozygote
‡ The two-tail t-test. §, suggestive linkage [22].
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Page 9 of 12development of PAH in humans [6]. Furthermore, it is
clearly shown that B6-specific genetic factors increase the
number of IL-17-producing CD4
+ T cells as well as
secretion of IL-13 and IFNg (data not shown) by lung tis-
sue resident CD4
+ T cells. IL-17 producing CD4 T cells,
namely Th17 cells are well known that participates in the
pathogenesis of various organ-specific autoimmune dis-
eases, such as inflammatory bowel disease and rheuma-
toid arthritis [36,37]. Although the role of Th17 cells in
PAH in humans has not been determined, our present
findings suggest that they indeed play a role in PAH. IL-
13 serves as an important mediator in pulmonary inflam-
mation [5,38,39], suggesting a causal contribution of IL-
13 to the pathogenesis of the present model. The pre-
sence of immunological findings provides an insight into
PAH-prone immune condition in the lung: the increase
of proinflammatory effectors, IL-13 and Th17, and the
decrease of an anti-inflammatory effector, Treg.
The present genome-wide genetic approach demon-
strated a new susceptibility locus controlling the onset of a
PAH-like disease in our model. Previous genetic studies
performed on familial PAH have shown mutations in 2
genes responsible for susceptibility to PAH: bone morpho-
genetic protein receptor 2 gene (BMPR2) [40] and activin-
like kinase type-1 gene (ALK-1) [41]. Our identified locus
includes neither of these genes, nor, to the best of our
knowledge, any gene involved in their signal transduction
pathways. However, Nos3 and Hgf genes were particularly
noted within this locus. Nitric oxide (NO) is known as a
potent endothelial cell-derived vasodilator and an inhibitor
of smooth muscle proliferation. Endothelial NO produc-
tion largely depends on NOS3/eNOS (encoded by Nos3).
NOS3-deficient mice showed reduced pulmonary vascular
proliferation and remodeling to chronic hypoxia [42,43].
Several studies have reported the preventive role of NO in
the development of PH in mice and humans. The poly-
morphism of human Nos3 gene is associated with high-
altitude pulmonary edema and PH in patients with chronic
obstructive pulmonary disease [44]. On the other hand,
Hgf, which encodes hepatocyte growth factor (HGF), sup-
presses vascular medial hyperplasia and matrix accumula-
tion in advanced PH in rats [45]. These findings have
underscored the role of NOS3/eNOS or HGF as a patho-
genic modifier in the present PH model.
A T-cell subset, type II helper T cell (Th2), plays an
important role in the pathogenesis of PAH in mice [39].
In this regard, it is noteworthy that the 2 loci (the trans-
gene locus and the susceptibility locus) have a strong
impact on Th1/Th2 balance. The OX40 signal promotes
a Th2-prone condition in mice [34]. On the other hand,
NO and HGF serve as inducible factors for type I helper
T cells (Th1) [46,47]. Therefore, in the TgL strains of
mice, the 2 loci are mutually counterbalanced, and the
net Th1/Th2 proportion depends mainly on the poly-
morphic effect of the susceptibility locus. In a B6 genetic
background, an effect of the susceptibility locus may
suppress Th1 responses and maximize Th2 augmenta-
tion in the lung conferred by the OX40L transgene,
resulting in the B6-specific onset of PH.
Conclusion
The present study reported a novel transgenic mouse
model for PH. This model differs from previous PH
models, which include a hypoxia-induced model, a
drug-induced model, and a genetic model (i.e., endothe-
lin B receptor-deficient) [48], in etiology, histopathology,
and spontaneity of PH. Considering the physiological
functions of OX40L, it is likely that the development of
PH in the present model depends on Th2-mediated
mechanisms. The present model may provide a new
experimental opportunity for investigating immune-
mediated mechanisms underlying PAH and the develop-
ment of immune-targeted therapy for PAH.
Additional material
Additional file 1: Summary of genome wide scan. Genotypes of
BCN2.TgL mice were determined by polymerase chain reaction (PCR)
using genomic DNA for 98 microsatellite positions.
Figure 6 LOD plots of the QTL analysis for PAH scores on
chromosome 5. The significant threshold level (a = 0.05) is shown by
a score of 2 with a dashed line. The LOD peak (2.4) is located at 7 cM.
The Y-axis denotes the level of the LOD score, and the X-axis denotes
the genetic position defined by the microsatellite markers indicated:
D5Mit346 (1 cM), D5Mit381 (8 cM), D5Mit197 (36 cM), D5Mit338 (59 cM),
D5Mit213 (70 cM), and D5Mit409 (83 cM). The results were obtained
using the interval mapping program of the MapMarker/QTL software.
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Page 10 of 12Additional file 2: Pathological phenotypes in the lung of BALB.TgL
mice. (A) RVSP (mmHg) in BALB.TgL (35 w, male, n = 4) and wild-type B6
(28 w, male, n = 4). The difference in the average values between the
two strains is not statistically significant (p = 0.37, two tailed t test).
These RVSP values tended to be lower than those in our previous
measurement shown in Figure 2A. This change is probably due to the
difference in the experimental conditions. (B) Evaluation of RV
hypertrophy in BALB.TgL (35 w, male, n = 5) and wild-type B6 (28 w,
male, n = 5). RV hypertrophy was evaluated with the index of RV/(LV
+IVS). The difference between the two strains is not statistically
significant (p = 0.76, two-tailed t-test).
Additional file 3: Foxp3 expression on total CD4 versus CD25
negative effector CD4 T cells. Total CD4 and CD4+CD62L
lowCD25
negative cells from the lung tissue were stained for intracellular Foxp3.
List of Abbreviations
αSMA: Alpha smooth muscle actin; B6.TgL: OX40L transgenic on C75BL/6
strain; BALB. TgL: OX40L transgenic on BALB/c strain; H & E: Hematoxylin
and Eosin; HGF: Hepatocyte growth factor; IVS: Intraventricular Septum; LOD:
Logarithm of odd; LV: Left ventricular; MCTD: Mixed connective tissue
disease; NO: Nitric oxide; OX40L: OX40 ligand; PH: Pulmonary hypertension;
PAH: Pulmonary arterial hypertension; PMA: phorbol 12-myristate 13-acetate;
QTL: quantitative trait locus; RV: Right ventricle; RVSP: Right ventricular
systolic pressure; Th: T helper cells; T reg: regulatory T cell; TNFSF: Tumor
necrosis super-family
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